SCM
CNST

Silverarc Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Silverarc Capital Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-25,200
Closed -$726K – 110
2020
Q4 		$726K Buy
+25,200
New +$634K 0.42% 60

Other funds holding CNST

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Silverarc Capital Management's CNST Position: Q1 2021 in Review

Silverarc Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q1 2021, closing a stake of 25,200 shares — an estimated $726K sold.

Silverarc Capital Management first reported a position in CNST in Q4 2020 and held it in 1 quarter. The position peaked at $726K in Q4 2020. 131 funds tracked by Wall St. Rank hold CNST as of Q1 2021.

  • Silverarc Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 25,200 Constellation Pharmaceuticals, Inc. shares in Q1 2021, an estimated $726K.
  • Silverarc Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Silverarc Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $726K in Q4 2020.
  • 131 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q1 2021.

Based on Silverarc Capital Management's 13F filing for Q1 2021, filed 18 May 2021.